Sport decision note · O-050
TUEs, strict liability and peptide products in sport
The athlete remains responsible for what enters their body. A seller assurance, ingredient omission or contamination claim does not prevent an anti-doping rule violation from being established.
Strict liability means an athlete can commit an anti-doping rule violation when a prohibited substance or its markers are present, regardless of intent. A Therapeutic Use Exemption is a formal, evidence-based permission for necessary treatment; it is not a general peptide exemption or a retrospective explanation on demand.
Check every named medicine on Global DRO and the current Prohibited List, then use the UKAD TUE Wizard if treatment is prohibited. Keep the dated search record. For a supplement or unverified peptide vial, a label check cannot remove contamination or mislabelling risk.
What strict liability changes
Under anti-doping rules, the athlete has the personal duty to ensure that no prohibited substance enters their body. For presence, authorities do not need to prove that the athlete intended to cheat or knew the substance was present.
Intent and fault can still matter later, including when a sanction is assessed, but they do not erase the initial presence finding. “The seller said WADA safe” and “the label did not list it” are therefore weak control measures.
What a TUE does and does not do
The application and approval are separate events.
| Question | Evidence-based answer | Limit |
|---|---|---|
| Who needs one? | An athlete whose necessary treatment uses a prohibited substance or method, subject to their sport level and UKAD route. | A medication may be permitted, conditionally permitted or prohibited only in certain settings; check first. |
| When to apply? | National TUE Pool athletes usually need approval before treatment unless an exception applies. Other athletes may follow a retroactive route. | Retroactive eligibility is rule-based, not a promise that any late application will succeed. |
| What is assessed? | Medical diagnosis, clinical need, alternatives and the treatment plan are assessed against the TUE standard. | A seller recommendation or performance goal is not a clinical justification. |
| What is approved? | The certificate specifies the treatment details, effective period and conditions. | It does not cover undeclared ingredients, another product or a changed treatment plan. |
Why blends and unverified products multiply the risk
A multi-ingredient product requires every ingredient to be checked. One prohibited component is enough to create a problem, and an omitted or substituted substance may not appear in a label search.
Batch testing can reduce some supplement risk when a recognised programme tests the exact batch, but it never guarantees a product is free of every prohibited substance. A general certificate, seller badge or “WADA compliant” phrase is not a TUE and is not a defence.
Read why blends multiply the risk and how contamination and mislabelling break label-only checks.
A defensible athlete workflow
Complete this before treatment where the rules require advance approval.
- Confirm the exact medicine.Use the brand, active ingredients, route and country of purchase.
- Check Global DRO and the Prohibited List.Save the search reference and date.
- Tell the clinician you compete under anti-doping rules.Discuss permitted alternatives where clinically appropriate.
- Use the UKAD TUE Wizard.Follow the route for your competition level and circumstances.
- Wait for the decision when advance approval is required.An application receipt is not permission.
- Keep the certificate current.Report treatment changes and retain medical records.
See the sport framework in full and the step-by-step list check.
Source ledger
Primary guidance and standards checked on 8 August 2026.
- UK Anti-Doping: the Prohibited List · Athletes are strictly liable for prohibited substances found in their sample.
- UK Anti-Doping: checking medications · Use Global DRO and keep a search record; a TUE may be needed before treatment.
- UK Anti-Doping: how to apply for a TUE · Advance and retroactive routes depend on the athlete’s pool and the circumstances; an application is not an approval.
- UK Anti-Doping: managing supplement risks · No supplement is risk-free and batch testing reduces rather than removes risk.
Follow the adjacent evidence
Questions people ask
Does strict liability mean intent never matters?
Intent is not required to establish a presence violation. Fault and intent may still affect other charges or the sanction, but they do not make a positive finding disappear.
Is a seller’s “WADA safe” claim reliable?
No. WADA does not approve retail peptide products. The athlete must check the current rules, and a seller cannot rule out undeclared ingredients, contamination or a future list change.
Can I apply for a TUE after a positive test?
Some athletes and exceptional circumstances permit a retroactive application, but eligibility and approval are rule-based. It is not a universal fallback. Follow UKAD’s route immediately.
Does submitting a TUE application mean I can start treatment?
Not when advance approval is required. An application is not an approval. Medical emergencies have specific retroactive provisions; follow UKAD guidance and keep complete clinical records.
Does a TUE cover a contaminated peptide product?
A TUE covers the specified medically necessary treatment and its conditions. It does not grant permission for undeclared substances or an unrelated contaminated product.
Do I need to check every ingredient in a blend?
Yes. Check every named ingredient and remember that a label cannot rule out omissions or contamination. Blends add more prohibited-status and product-identity failure points.
Editorial experience
From our work: how we checked this page
For topical-map item O-050, TUEs, strict liability and peptide products in sport was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 4 unique external sources and 7 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Yianni Kiromitis checked the page against its mapped purpose, verified the cited sources, reviewed the internal routes and approved the final wording as Lead Author, Publisher and Managing Editor. This page does not carry a specialist review credit because its publication decision did not require a scientific or clinical conclusion beyond the named material it links to.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.